On July 21, 2015, the Federal Circuit reached a momentous decision in the case of Amgen vs. Sandoz. The significance of this ruling goes well beyond the rights of these particular manufacturers, as the decision marks the first step toward clarifying the regulatory path for U.S. biosimilar manufacturers.
Among the primary causes for attrition in early clinical development are safety and pharmacology issues. In the case of biopharmaceuticals, immunogenic and hypersensitivity reactions are perhaps the largest contributors to such early clinical failures
Watch the webinar now to learn how an innovative approach can improve the clinical trial experience and move medicine forward.
The relationships and considerations of bead structure, pore structure, surface chemistries and ligand design on affinity resin performance targets.